Alimera’s management team has a proven track record of product discovery, development and revenue growth in the ophthalmic pharmaceutical industry. Prior to founding Alimera, many members of the management team established CIBA Vision Ophthalmics, later Novartis Ophthalmics, the ophthalmic pharmaceutical arm of Novartis Corporation.
Since the founding of Alimera Sciences, the management team has raised approximately $145 million through private capital and completed a public offering in June 2010 for $72 million to invest in our products. With the substantial financial backing of our initial investors and public market shareholders, we have accomplished a great deal in a short time frame:
- Launched Soothe®, an over-the-counter (OTC) product that provides unique relief to sufferers of dry eye
- Gained FDA NDA approval for an Rx-to-OTC switch anti-allergy product (now marketed by Bausch and Lomb as Alaway® - ketotifen fumarate ophthalmic solution)
- Completed two Phase 3 clinical trials with ILUVIEN® studying the long-term delivery of a low dose of a steroid for the treatment of diabetic macular edema
- Submitted regulatory applications for ILUVIEN with the US FDA and 7 European health authorities
- ILUVIEN® has received its marketing authorization approval in Austria, France, Germany, Portugal, Spain and the United Kingdom for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies, and is going through the national phase in the approval process in Italy. Alimera Sciences is still seeking approval in the United States. The proposed treatment consists of a tiny, cylindrical polymide tube that contains 190 µg of fluocinolone acetonide (FAc), a corticosteroid. Corticosteroids have a with a history of treating ocular diseases. Learn More >>
- Developed a pipeline for the future success of Alimera Sciences
The executive team's operational experience, regulatory expertise, clinical knowledge and industry relationships have coalesced into immediate success and built the foundation for a strong future.
President and Chief Executive Officer
Dan Myers is the co-founder of Alimera Sciences, Inc. and has served as its
President and CEO since 2003. Under his leadership Alimera has raised Series A,
Series B and Series C venture funding totaling approximately $106M and went
public in April of 2010 raising $72M in additional capital. The company
recently completed a $40 million round of financing in preparation of the
launch of its lead product, ILUVIEN. Alimera was the Georgia BIO “Deal of the
Year” in 2004 and 2005 as well as the Southeastern BIO “Strategic Deal of the
Year” in 2010.
Prior to Alimera, Dan was a founding member of Novartis Ophthalmics
(formerly CIBA Vision Ophthalmics) and served as Vice-President of Sales and
Marketing and later as President from 1997 through 2002. Dan has 30 years of
sales, marketing and general management experience in the ophthalmic
pharmaceutical industry through tenures at Novartis, Allergan, and Johnson
& Johnson. Dan has been a member of the American Academy of Ophthalmology
Corporate Advisory Council, active in the Foundation Fighting Blindness and
former Board Member of Prevent Blindness America. In addition, he has served on
the Carter Foundation Board of Councilors in Atlanta and currently sits on the
Board of the Georgia BIO and Southeastern BIO.,. Dan has a degree in Industrial
Management from the Georgia Institute of Technology and sits on the school’s
Alexander Tharpe Fund Board of Directors.
Senior Vice President and European Managing Director
Philip Ashman, Ph.D. joined Alimera Sciences in January 2013 as Senior Vice President and European Managing Director and leads the company’s European operations, Alimera Sciences Limited, headquartered in the United Kingdom. In this role, he oversees the expansion of the Alimera brand, management of the commercial launch of ILUVIEN®, as well as development of our European growth strategy.
Philip has more than 20 years of experience in all aspects of pharmaceutical management. Most recently, he was responsible for leadership of the market access strategy in the U.K. for Bayer, covering all therapy areas including ophthalmology.
Also while at Bayer, he held numerous leadership roles, including serving as vice president responsible for setting strategy and early preparations for specialty medicines. He also served as Bayer Regional Business Unit Head (Europe) in Oncology, responsible for the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East and Africa.
Philip holds a doctorate in biochemistry from the University of London: Royal Holloway and Bedford, U.K., and a Bachelor of Science degree in biochemistry from the University College London, U.K.
Senior Vice President, Regulatory and Medical Affairs
Susan is Senior Vice President of Regulatory and Medical Affairs and also has overall responsibility for QA/Compliance, Technical Drug Development, Manufacturing and Logistics at Alimera Sciences, Inc. Susan and her team are also responsible for post-marketing drug surveillance, drug safety and phase IV clinical studies. Since joining Alimera in March 2004, her team has filed and received approval for three INDs, obtained approval for one NDA in the US, filed Clinical Trial Applications in several countries (Canada, the EU and India), and filed electronic Common Technical Document (e-CTD) for ILUVIEN with the FDA and 7 European health authorites.
Immediately prior to Alimera, Susan was the Vice President of Regulatory and Medical Affairs at Novartis Ophthalmics. She has twenty three years of ophthalmic regulatory experience having worked with Allergan, J&J, Alcon and Novartis. Her product development background includes drugs (human and animal), ophthalmic irrigating solutions, contact lenses and contact lens care, viscoelastics, intraocular lenses, ophthalmic surgical instruments and equipment - both US and international. Susan has been responsible for twelve NDA and several ANDA FDA approvals. Susan has a BS and Masters degrees in Chemistry.
Chief Operating Officer and Chief Financial Officer
Rick joined Alimera Sciences in 2005 as our CFO and assumed the position of COO in 2010. He is responsible for strategic finance, accounting, distribution logistics, human resources and information technology. Rick brings a wealth of financial and operational management experience with both public and private ventures. Since joining Alimera, he led our Series C and C-1 venture funding totaling approximately $47M. In 2010 Rick led our successful IPO, raising $72M, and negotiated a $32.5 million credit facility leading to recognition of Alimera as the "Strategic Deal of the Year" by both Southeastern BIO and Georgia BIO.
Rick has been active in Atlanta business for more than 20 years, with experience that includes financial and accounting management, mergers and acquisitions, and initial public offerings, as well as entrepreneurial and start-up operational activities. Rick is the founder of two consulting practices, Brand Ignition Group and Black River Holdings, Inc. He is also the former chief financial officer and senior executive vice president of Netzee, Inc., a provider of internet banking solutions to community banks that went public in 1999. Rick started his career in Arthur Andersen’s audit and business advisory practice where he was a senior manager and a certified public accountant. Rick currently serves as the chairman of the board of directors and audit committee of Jones Soda Co., a Seattle-based publicly traded company, and vice-chairman of the North Metro Miracle League, an Atlanta-based charitable organization. He has an accounting degree from Wake Forrest University.
Ken Green, Ph.D.
Chief Scientific Officer
Ken Green, Ph.D., Chief Scientific Officer at Alimera Sciences, is responsible for all preclinical and clinical development activities supporting the company's portfolio. He provides input to the project teams regarding clinical and preclinical trial design and development strategy and supports the marketing and sales organizations with input to post-marketing study strategies. Additionally, he serves as a member of the executive committee helping to define the overall strategic direction of the company.
Prior to joining Alimera Sciences, Dr. Green worked with Lederle Laboratories, Storz Ophthalmics, Bausch & Lomb, CIBA Vision and Novartis Ophthalmics. At Novartis Ophthalmics, Dr. Green served as the Global Head of Clinical Science, where he was involved with the development of Visudyne® (verteporfin for injection), Rescula® (unoprostone isopropyl ophthalmic solution .15%) and Zaditor® (ketotifen fumerate ophthalmic solution) in both the US and Europe.*
Dr. Green's ophthalmology experience spans 15 years and includes clinical development experience in the areas of allergy, infection, glaucoma, age-related macular degeneration, diabetic retinopathy and myopia. In 2003, Dr. Green presented to an FDA advisory panel convened to define a clinical endpoint for the pharmacological treatment of juvenile onset myopia.
Dr. Green earned his B.A. degree in chemistry from Southern Illinois University and a Ph.D. in organic chemistry from Ohio State University. He has published several scientific papers and is listed as an inventor on several U.S. patents.
Senior Vice President of Sales and Marketing
A co-founder, Dave has been the Vice President of Marketing since June 2003, and was named Senior Vice President of Sales and Marketing in 2010. He has been instrumental in obtaining the venture funding, has lead the development of the Alimera brand, has launched Soothe® Emollient (Lubricant) Eye Drops, and is in the process of developing the launch plans for Alimera's next brands.
Prior to Alimera, Dave spent eighteen years marketing ethically-promoted OTC and prescription pharmaceuticals, including the launch of 16 new products. For five years, Dave was Vice President of Marketing with Novartis Ophthalmics following other marketing positions at CIBA Vision Ophthalmics, which he joined in 1992. Dave also has international management experience having been responsible for the global launch of CIBA Vision's daily disposable contact lenses. Prior to Novartis, Dave spent four years in the Procter and Gamble brand management program and was on the team that launched its first pharmaceutical product. Dave has served on the Corporate Advisory Council for Ocular Surgery News, the industry's leading publication and is a board member of a local financial services company. He has a BA in politics from Princeton University.
* Rescula®, Visudyne® and Zatidor® are registered trademarks of Novartis AG.